, Andrew N. Hill, Adam J. Langer, and Julie L. Self
Figure 4. Comparison of National Tuberculosis Surveillance System (NTSS) case counts and IQVIA projected patient counts for isoniazid or pyrazinamide prescriptions, United States, 2020. A, B) Projected patient counts for isoniazid (A) and pyrazinamide (B). Horizontal axis of each plot shows NTSS patient counts aggregated by treatment start date (month), removing patients who had reported resistance. Each point represents a month in 2020. The Pearson correlation coefficient (r) is shown in lower righthand corner of each plot. C, D) A linear model fit to the 2006–2019 data (Figure 1) with quarter as a covariate to predict 2020 IQVIA projected patient counts for isoniazid (C) or pyrazinamide (D). Black line indicates actual data; gray line indicates expected IQVIA counts with 95% prediction intervals. Note vertical axes are different because of different scales for isoniazid and pyrazinamide in the IQVIA dataset. NTSS, National Tuberculosis Surveillance System.